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Abstract
Background:  Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a
variety of cancer types; however, unacceptable toxicity profiles have hindered the development of
drugs. RAR agonists presenting novel structural and chemical features could therefore open new
avenues for the discovery of leads against breast, lung and prostate cancer or leukemia.
Results:  We have analysed the induced fit of the active site residues upon binding of a known
ligand. The derived binding site models were used to dock over 150,000 molecules  in silico (or
virtually) to the structure of the receptor with the Internal Coordinates Mechanics (ICM) program.
Thirty ligand candidates were tested in vitro.
Conclusions:  Two novel agonists resulting from the predicted receptor model were active at 50
nM. One of them displays novel structural features which may translate into the development of
new ligands for cancer therapy.
Background
The retinoic acid receptors (RAR-α , -β , and -γ ) are tran-
scription factors regulating a variety of endocrine meta-
bolic pathways. Unlike anti-estrogens, such as tamoxifen
or raloxifene, ligands targeted against the RAR isoforms
can present anticancer activity against both estrogen re-
ceptor positive and negative breast tumor cells [1]. As a
result, such molecules could constitute a novel genera-
tion of drugs against breast cancer. For reasons not yet
clear, both agonists and antagonists of RAR can present
anti-tumor activity against breast, prostate, lung cancer
or leukemia [1,2,3,4,5,6,7]. The development of both
types of ligands could therefore have important biomed-
ical implications. We have recently demonstrated that
antagonists could be discovered rationally, based on a
model of the antagonist-bound conformation of the re-
ceptor [8]. Our goal here is to discover innovative molec-
ular structures with RAR agonist activity.
Several retinoid and non-retinoid ligands have been de-
scribed, which activate one or a combination of RAR iso-
forms. Some of them, such as the natural hormone all-
trans retinoic acid (all-trans RA) (Fig. 1a), have been
tested clinically, and display unacceptable side effects,
such as skin dryness, cheilitis, hypertriglyceridemia and
conjunctivitis [9,10]. However, the compounds tested so
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far belong to limited series of related structures. An in-
creasing amount of data suggests that the RAR-β  iso-
form, which is under the transcriptional control of RAR-
α , is involved in suppressing cell growth and tumori-
genicity [11,12,13,14,15,16]. Innovative molecules with
RAR-α  and RAR-β  agonist activity could therefore
present more favorable toxicity profile than pan-ago-
nists.
We applied a flexible virtual screening algorithm (Mol-
soft ICM, virtual library screening module [17]) which
rapidly docks hundreds of thousands of flexible com-
pound structures into the ligand binding pocket of RAR,
and discovered two novel RAR-β  selective agonists. One
of these ligands displays original structural and chemical
characteristics, which could be used in the development
of novel compounds for cancer prevention and therapy.
Results and discussion
We first built a model of the RAR-α  agonist binding
pocket from the crystal structure of the RAR-γ  ligand
binding domain (RAR-γ  LBD) / all-trans RA complex
[18]. All but three amino acids in the vicinity of the ligand
are conserved between the two isoforms. These three
non-identical residues -A234, M272, and A397- were
changed to the RAR-α  isoform -S234, I272 and V397-
and the energy of the system was minimized (see "Mate-
rials and Methods").
In order to address the accuracy of our model of the
RAR-α  binding pocket, we docked Am580, an RAR-α
specific agonist [19], into the receptor (the chemical
structure of Am580 is shown Fig. 1b). A rapid docking
procedure with flexible ligand and a grid representation
of the receptor was followed by an extensive Monte Carlo
energy minimization with both ligand and receptor side
Figure 1
Chemical structure of the RAR ligands discussed in this work. A: All-trans retinoic acid. B: 4- [(5,6,7,8-tetrahydro- 5,5,8,8-
tetramethyl-2- naphthalenyl) carboxamido] benzoic acid (Am580). C: 2- (4- carboxyphenyl)- 4- (3-trifluoromethylphenyl) thia-
zole (Agonist 1). D: 4- (3-(3,5- di-tert-butyl- 4-hydroxyphenyl)-3- oxopropenyl) benzoic acid (Agonist 2) E: 3,5-di-tert-butyl-
chalcone 4'-carboxylic acid (Ch55)BMC Structural Biology (2001) 1:1 http://www.biomedcentral.com/1472-6807/1/1
chains flexible (see "Materials and Methods" for details).
The ligand superimposed well with the natural hormone
all-trans RA (Fig. 2a). Interestingly, Am580 does not
seem to fit in the receptor binding site: the ketone oxygen
of the ligand sticks out of the binding pocket, due to too
close proximity of residue 234 (Fig. 2b). However, in the
complex with RAR-α , this ketone oxygen shares an hy-
drogen atom with the hydroxyl group of serine 234, and
forms a stabilizing hydrogen bond, while a steric clash
occurs in the other two RAR isoforms, where residue 234
is an alanine. Consequently, our model provides a ration-
al for Am580 isoform specificity, suggesting that it is rel-
evant and could be used as a template for the discovery
of novel RAR-α  agonist structures.
A high throughput virtual screening was carried out on
the Available Chemicals Directory (MDL Information
Systems, San Leandro, CA), a compound structure data-
base of over 150,000 molecules. Each compound was au-
tomatically docked into a grid representation of RAR-α ,
as previously described for Am580, and assigned a score
according to the quality of the fit [8, 17, 20]. The 5364 lig-
and candidates which scored better (i.e. lower) than -32
kcal/mol were preselected for a more refined energy
minimization procedure, with flexible receptor side
chains, and the energy of complexation was predicted as
previously described [21] (see "Materials and Methods").
After careful visual examination of the 300 candidates
displaying the lowest predicted binding energy, 30 mol-
ecules were selected and purchased to be experimentally
tested in vitro.
HeLa cells were separately transfected with either of the
three wild type hRAR isoforms, and a ∆ MTV-IR-CAT re-
porter gene [22, 23]. The cells were incubated with each
ligand at concentrations from 50 nM to 20 µ M to stimu-
late CAT activity. Possible toxicity of the compounds was
deduced from the amount of cellular protein extract after
2 days of incubation. The percentage of conversion in-
duced by 1 µ M all-trans RA (RARs) or 1 µ M 9-cis RA
(RXR-β ) was used as a positive control to determine the
maximum induction. Fig. 3 shows all-trans RA induced
conversion of RAR-α  as a function of acid concentration.
RAR-β  could induce 20% of the maximum CAT activity
when activated by 50 nM agonist 1 (chemical structure
shown Fig. 1c), while RAR-γ  was only 12% active and
RAR-α  not active at all under the same conditions (Fig.
4). At 200 nM of agonist 1, RAR-β  was 50% active, RAR-
γ  25% and RAR-α  5% active. Similarly, RAR-β  could in-
duce 22% of the maximum CAT activity when activated
by 50 nM agonist 2 (chemical structure shown Fig. 1d).
RAR-α  and RAR-γ  were 10% and 14% active at the same
concentration of agonist, respectively. At 200 nM of ag-
onist 2, RAR-β  displayed 48% of its maximal activity,
RAR-α  40% and RAR-γ  17%. At 20 µ M, agonist 1 induced
full activation of RAR-β  and RAR-γ , and 80% activation
of RAR-α , showing that this compound is a full agonist.
Agonist 2 was toxic for the cells at 20 µ M, as shown by
protein content of cell culture dishes, which is why little
transcriptional activity was observed at this concentra-
tion. However, little or no toxicity was observed at 8 µ M,
a concentration at which agonist 2 induced about 50%
maximal activity of RAR-α  and RAR-β , and 35% maxi-
mal activity of RAR-γ . Agonist 1 was not toxic at 20 µ M.
Finally, RXR-β  was activated only weakly by both ago-
nists 1 and 2 at 2 µ M, but was significantly activated by
agonist 1 at 20 µ M (Fig. 4). Comparison of Figs. 3 and 4
also shows that at 200 nM of agonists 1 and 2, RAR-β  ex-
hibits the same activity as the positive control RAR-α  in-
duced by all-trans RA at the same concentration.
Figure 2
Docking  of  a  known  RAR-α   specific  agonist.  The  RAR-α
selective agonist Am580 was docked into the modeled ligand
binding pocket of RAR-α  . A: The complexed ligand (white
sticks) superimposes with the crystal structure of bound all-
trans RA (green). Hydrogens are not shown for clarity. B:
Am580 (CPK display) fits tightly into the receptor's pocket
( y e l l o w  w i r e ) ,  b u t  f o r  a  ke t o n e  o x y g e n ,  w h i c h  s h a r e s  a n
hydrogen with Ser234 of the receptor (displayed as stick).
The receptor in the vicinity of the ligand is shown as a white
ribbon.  Carbons,  hydrogens,  oxygens  and  nitrogen  are
colored white, gray, red and blue respectively. (Image gener-
ated with Molsoft ICM)BMC Structural Biology (2001) 1:1 http://www.biomedcentral.com/1472-6807/1/1
The predicted structure of the complex generated by the
virtual screening approach, and further optimized with
flexible receptor side-chains details clearly the interac-
tions between the receptor and the ligands (Fig. 5). Ago-
nist  1 and 2 both have a carboxylate group which
superimposes with the carboxylate of all-trans RA, and
makes stabilizing hydrogen bonds with Arg 274 and 278,
and the backbone nitrogen of Ser 289 (Fig. 5). All other
receptor/ligand interactions are hydrophobic. As a re-
sult, the size and flexibility of the ligand as well as the
shape complementarity with the receptor are critical for
affinity and specificity.
The structure of agonist 2 is almost similar to that of
Ch55 (Fig. 1e), another RAR-β  selective agonist [24] with
0.44, 0.04 and 1.7 nM Kd for RAR-α , RAR-β  and RAR-γ
respectively [4]. However, agonist 2 has an additional
hydroxyl group on the aromatic ring. The observation
that Ch55 displays some potency against the growth of
human non-small cell lung carcinoma cells [4] as well as
anti-angiogenic activity [25] suggests that agonist 2 is a
good lead candidate for cancer therapy. Since this com-
pound was discovered through a single virtual library
screening, this is a very encouraging result which also
constitutes a validation of our method.
The structure of agonist 1 is entirely novel; it is the first
RAR ligand described so far with either a thiazole ring or
a trifluoro group. It presents a very limited level of flexi-
bility and fits tightly into the receptor's binding pocket.
This compound illustrates the benefits of the in silico
screening procedure, a rational approach which is based
solely on the structure of the receptor, and is not biased
towards existing ligands. Indeed, structure-based drug
design usually derives novel compound structures from
ligands previously described. Our approach enabled the
discovery ab initio of RAR agonists displaying some ac-
tivity at 50 nM with a 7% success rate.
The specificity profile of the two RAR ligands described
here are similar to that of Ch55, a compound with ten
times higher affinity for RAR-β  than RAR-α , and which
can block the growth of certain cancer types [4]. It will be
interesting to test these molecules for anti-proliferative
activity, both in vitro and in vivo. The observation that
agonist 1 does not belong to any of the series of RAR lig-
ands described so far makes this compound particularly
interesting for further development.
While a model of RAR-α  was used to conduct the virtual
screening, agonists 1 and 2 have an EC-50 of 200 nM for
RAR-β , and an EC-50 of 4 and 2 µ M respectively for
RAR-α . This observation emphasizes the primary goal of
structure-based screening procedures, which is to signif-
icantly accelerate the initial steps of lead identification
projects by automatically discriminating between bind-
ers and non-binders, rather than ranking ligands accord-
ing to their affinity for the receptor. The discovery of 2
RAR-α  agonists out of 30 molecules tested is a good illus-
tration of this approach.
Conclusions
This report details the rapid discovery of RAR agonists
with novel structural features, thanks to a powerful vir-
tual ligand screening approach, and a research strategy
where considerations on existing ligands are avoided.
One of the molecules presented here constitute a good
framework for the development of a novel series of RAR
ligands very different from all structures described so
far. Such ligands could present more favorable specificity
and toxicity profiles, and have important applications in
cancer therapy.
Materials and Methods
Modeling of RAR-alpha ligand binding pocket
The crystal structure of RAR-γ -LBD complexed to all-
trans RA was used as a template [18] and the three resi-
dues in the vicinity of the ligand which are not conserved
between the two isoforms were modified accordingly:
A234, M272, and A397 were changed to S234, I272 and
V397 respectively. The rotation variables of the side
chains within 3.5 Å of the modified residues were unfixed
and the energy of the system was minimized in the inter-
nal coordinate space, according to the ICM method [26,
29].
Figure 3
All-trans Retinoic Acid Mediates Dose-Dependent Transcrip-
tional Activation of the IR-CAT Reporter by RAR-α .BMC Structural Biology (2001) 1:1 http://www.biomedcentral.com/1472-6807/1/1
Docking of AM580 into RAR-alpha
The flexible ligand was docked into a combination of five
potential map representations of the RAR-α  ligand bind-
ing pocket, which account for two Van der Waals bound-
aries, hydrophobicity, electrostatics and hydrogen
bonding profiles [20,27]. This rapid docking procedure
was followed by a more refined energy minimization of
the complex, with a full atom representation of the re-
ceptor, and flexible receptor side chains, according to the
ICM stochastic global optimization algorithm [26, 27] as
implemented in the Molsoft ICM 2.7 program [17].
Virtual screening of the compound structure database
The ICM program [17] was used to perform both receptor
modeling and virtual ligand screening. The procedure
followed was similar than previously described [8]: each
flexible ligand of the Available Chemicals Directory
(MDL Information Systems, San Leandro) was docked
automatically into the combination of potential maps de-
scribed above, and assigned a score according to its fit
with the receptor. The scoring function included contin-
uum as well as discreet electrostatics, hydrophobicity
and entropy parameters [20]. The screening of the data-
base of over 150,000 ligands took less than a month on
10 "194 MHZ IP25" processors. Using the same comput-
ing power, the 5364 compounds which scored better (i.e.
lower) than -32 were preselected for a second automatic
round of selection: they were all docked in two days into
a full atom representation of the receptor, with flexible
receptor side chains, according to a global energy optimi-
zation in internal coordinates [17, 26,27,28]. The struc-
ture generated by the initial library screening was used
as a starting point for this second, more refined, docking
procedure. The binding energy of the compounds was
then evaluated with a boundary elements implementa-
tion of solvation electrostatics [21] and the 300 com-
pounds showing the lowest binding energy were selected
for further examination. After careful visual inspection
for shape complementarity, hydrogen bonding network,
compound flexibility, and potential Van der Waals clash-
Figure 4
In vitro activity of the novel RAR agonists. HeLa cells were separately transfected with a vector expressing each isoform of the
full-length receptor and a ∆ MTV-IR-CAT reporter gene. The CAT activity induced by each ligand at concentrations from 50
nM to 20 µ M was measured. The activity induced by the natural hormone all-trans RA at 1 µ M was used as the reference for
maximal induction for RARs, and 1 µ M 9-cis RA was used for RXR-β . The activity plotted is the observed percentage of this
maximal induction.BMC Structural Biology (2001) 1:1 http://www.biomedcentral.com/1472-6807/1/1
es, 30 molecules out of 300 were selected and purchased
to be experimentally tested in vitro. We should stress out
here that the Van der Waals term is too noisy to be added
to the binding energy function, as discussed in details
elsewhere [21]. As a consequence, some compounds with
a low predicted binding energy were not retained, be-
cause they seemed likely to clash sterically with the re-
ceptor.
Biological activity of the ligand candidates
HeLa cells were transfected by calcium phosphate pre-
cipitation using 1 µ g of plasmid expressing the full length
receptor isoform and 1 µ g of a ∆ MTV-IR-CAT reporter
gene, as previously described [22, 23]. Ligands were dis-
solved in DMSO at 20 mM final concentration. Cell cul-
tures were supplemented with indicated ligands
immediately after addition of the calcium phosphate/
DNA precipitate. Media and ligands were replaced after
24 h and cells were harvested and assayed for CAT activ-
ity 24 h later: acetylated and unreacted [14C] chloram-
phenicol was excised from a thin layer chromatography
plate and quantitated in a liquid scintillation counter.
The amount of cellular protein extract after two days of
incubation was measured to determine the compounds
toxicity. Agonist 1 was purchased from Bionet Research
(catalog number 1G-433S). Agonist 2 was purchased
from Sigma-Aldrich (Sigma Aldrich library of rare chem-
icals. Catalog number S08503-1).
Figure 5
Structure of the novel RAR agonists. Agonists 1 and 2 are shown (respectively A and B). Left: chemical structure of the com-
pounds. Right: Representation of the compounds docked into the binding pocket of RAR (important residues are displayed as
sticks: R274, R278, S289), and superimposed with the crystal structure of all-trans RA (green). The receptor is represented as
a white ribbon. Hydrogens are not displayed for clarity. Color coding: carbons, oxygens, nitrogens, sulfurs, fluorides and hydro-
gens are colored white, red, blue, yellow, magenta and gray respectively.BMC Structural Biology (2001) 1:1 http://www.biomedcentral.com/1472-6807/1/1
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